These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37198536)

  • 1. Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity.
    van Dam KPJ; Volkers AG; Wieske L; Stalman EW; Kummer LYL; van Kempen ZLE; Killestein J; Tas SW; Boekel L; Wolbink GJ; van der Kooi AJ; Raaphorst J; Takkenberg RB; D'Haens GRAM; Spuls PI; Bekkenk MW; Musters AH; Post NF; Bosma AL; Hilhorst ML; Vegting Y; Bemelman FJ; Voskuyl AE; Broens B; Sanchez AP; van Els CACM; de Wit J; Rutgers A; de Leeuw K; Horváth B; Verschuuren JJGM; Ruiter AM; van Ouwerkerk L; van der Woude D; Allaart RCF; Teng YKO; van Paassen P; Busch MH; Jallah PBP; Brusse E; van Doorn PA; Baars AE; Hijnen DJ; Schreurs CRG; van der Pol WL; Goedee HS; Steenhuis M; Keijzer S; Keijser JBD; Cristianawati O; Ten Brinke A; Verstegen NJM; van Ham SM; Rispens T; Kuijpers TW; Löwenberg M; Eftimov F;
    BMC Infect Dis; 2023 May; 23(1):332. PubMed ID: 37198536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapy.
    Stalman EW; Wieske L; Keijser JBD; van Dam KPJ; Kummer LYL; Wilbrink MF; van Kempen ZLE; Killestein J; Volkers AG; Tas SW; Boekel L; Wolbink GJ; van der Kooi AJ; Raaphorst J; Löwenberg M; Takkenberg RB; D'Haens GRAM; Spuls PI; Bekkenk MW; Musters AH; Post NF; Bosma AL; Hilhorst ML; Vegting Y; Bemelman FJ; Voskuyl AE; Broens B; Parra Sanchez A; van Els CACM; de Wit J; Rutgers A; de Leeuw K; Horváth B; Verschuuren JJGM; Ruiter AM; van Ouwerkerk L; van der Woude D; Allaart RCF; Onno Teng YK; van Paassen P; Busch MH; Brusse E; van Doorn PA; Baars AE; Hijnen D; Schreurs CRG; van der Pol WL; Goedee HS; Steenhuis M; Keijzer S; Cristianawati O; Brinke AT; Verstegen NJM; Zwinderman KAH; van Ham SM; Rispens T; Welkers MR; Jonges M; Eftimov F; Kuijpers TW;
    J Allergy Clin Immunol; 2024 Sep; 154(3):754-766.e7. PubMed ID: 38763170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies.
    Boekel L; Stalman EW; Wieske L; Hooijberg F; van Dam KPJ; Besten YR; Kummer LYL; Steenhuis M; van Kempen ZLE; Killestein J; Volkers AG; Tas SW; van der Kooi AJ; Raaphorst J; Löwenberg M; Takkenberg RB; D'Haens GRAM; Spuls PI; Bekkenk MW; Musters AH; Post NF; Bosma AL; Hilhorst ML; Vegting Y; Bemelman FJ; Voskuyl AE; Broens B; Parra Sanchez A; van Els CACM; de Wit J; Rutgers A; de Leeuw K; Horváth B; Verschuuren JJGM; Ruiter AM; van Ouwerkerk L; van der Woude D; Allaart CF; Teng YKO; van Paassen P; Busch MH; Jallah PBP; Brusse E; van Doorn PA; Baars AE; Hijnen DJ; Schreurs CRG; van der Pol WL; Goedee HS; Vogelzang EH; Leeuw M; Atiqi S; van Vollenhoven R; Gerritsen M; van der Horst-Bruinsma IE; Lems WF; Nurmohamed MT; Boers M; Keijzer S; Keijser J; van de Sandt C; Boogaard A; Cristianawati O; Ten Brinke A; Verstegen NJM; Zwinderman KAH; van Ham SM; Rispens T; Kuijpers TW; Wolbink G; Eftimov F;
    Lancet Rheumatol; 2022 Jun; 4(6):e417-e429. PubMed ID: 35527808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study.
    Christensen IE; Jyssum I; Tveter AT; Sexton J; Tran TT; Mjaaland S; Kro GB; Kvien TK; Warren DJ; Jahnsen J; Munthe LA; Haavardsholm EA; Vaage JT; Grødeland G; Lund-Johansen F; Jørgensen KK; Syversen SW; Goll GL; Provan SA
    BMC Med; 2022 Oct; 20(1):378. PubMed ID: 36199139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Cytokine Inhibitor Therapy on the Prevalence, Seroconversion Rate, and Longevity of the Humoral Immune Response Against SARS-CoV-2 in an Unvaccinated Cohort.
    Simon D; Tascilar K; Kleyer A; Fagni F; Krönke G; Meder C; Dietrich P; Orlemann T; Kliem T; Mößner J; Liphardt AM; Schönau V; Bohr D; Schuster L; Hartmann F; Leppkes M; Ramming A; Pachowsky M; Schuch F; Ronneberger M; Kleinert S; Hueber AJ; Manger K; Manger B; Atreya R; Berking C; Sticherling M; Neurath MF; Schett G
    Arthritis Rheumatol; 2022 May; 74(5):783-790. PubMed ID: 34951137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerated waning of immune responses to a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases.
    Mrak D; Kartnig F; Sieghart D; Simader E; Radner H; Mandl P; Göschl L; Hofer P; Deimel T; Gessl I; Kain R; Winkler S; Smolen JS; Perkmann T; Haslacher H; Aletaha D; Heinz LX; Bonelli M
    J Autoimmun; 2023 Feb; 135():102981. PubMed ID: 36706534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases.
    Stalman EW; Wieske L; van Dam KPJ; Kummer LY; van Kempen ZLE; Killestein J; Volkers AG; Tas SW; Boekel L; Wolbink GJ; Van der Kooi AJ; Raaphorst J; Löwenberg M; Takkenberg RB; D'Haens GRAM; Spuls PI; Bekkenk MW; Musters AH; Post NF; Bosma AL; Hilhorst ML; Vegting Y; Bemelman FJ; Voskuyl AE; Broens B; Parra Sanchez A; van Els CACM; Wit J; Rutgers A; de Leeuw K; Horváth B; Verschuuren JJGM; Ruiter AM; van Ouwerkerk L; van der Woude D; Allaart CF; Teng OYK; van Paassen P; Busch MH; Jallah PBP; Brusse E; van Doorn PA; Baars AE; Hijnen DJ; Schreurs CRG; Van der Pol WL; Goedee HS; Steenhuis M; Keijzer S; Keijser JBD; Boogaard A; Cristianawati O; Ten Brinke A; Verstegen NJM; Zwinderman KAH; Rispens T; van Ham SM; Kuijpers TW; Eftimov F;
    Ann Rheum Dis; 2022 Dec; 81(12):1757-1766. PubMed ID: 36357161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 infection and COVID19 vaccination across eight immune-mediated inflammatory disorders: A prospective, real-life Belgian cohort study - the BELCOMID study.
    Geldof J; Truyens M; Sabino J; Ferrante M; Lambert J; Lapeere H; Hillary T; Van Laethem A; de Vlam K; Verschueren P; Padalko E; Lobaton T; Vermeire S
    Front Immunol; 2023; 14():1126351. PubMed ID: 36936974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of immunosuppressive therapy on SARS-CoV-2 mRNA vaccine effectiveness in patients with immune-mediated inflammatory diseases: a Danish nationwide cohort study.
    Elmahdi R; Ward D; Ernst MT; Poulsen G; Hallas J; Pottegård A; Jess T
    BMJ Open; 2024 Feb; 14(2):e077408. PubMed ID: 38387988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study.
    Wieske L; van Dam KPJ; Steenhuis M; Stalman EW; Kummer LYL; van Kempen ZLE; Killestein J; Volkers AG; Tas SW; Boekel L; Wolbink GJ; van der Kooi AJ; Raaphorst J; Löwenberg M; Takkenberg RB; D'Haens GRAM; Spuls PI; Bekkenk MW; Musters AH; Post NF; Bosma AL; Hilhorst ML; Vegting Y; Bemelman FJ; Voskuyl AE; Broens B; Sanchez AP; van Els CACM; de Wit J; Rutgers A; de Leeuw K; Horváth B; Verschuuren JJGM; Ruiter AM; van Ouwerkerk L; van der Woude D; Allaart RCF; Teng YKO; van Paassen P; Busch MH; Jallah PBP; Brusse E; van Doorn PA; Baars AE; Hijnen DJ; Schreurs CRG; van der Pol WL; Goedee HS; Keijzer S; Keijser JBD; Boogaard A; Cristianawati O; Ten Brinke A; Verstegen NJM; Zwinderman KAH; van Ham SM; Kuijpers TW; Rispens T; Eftimov F;
    Lancet Rheumatol; 2022 May; 4(5):e338-e350. PubMed ID: 35317410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases.
    Wieske L; Kummer LYL; van Dam KPJ; Stalman EW; van der Kooi AJ; Raaphorst J; Löwenberg M; Takkenberg RB; Volkers AG; D'Haens GRAM; Tas SW; Spuls PI; Bekkenk MW; Musters AH; Post NF; Bosma AL; Hilhorst ML; Vegting Y; Bemelman FJ; Killestein J; van Kempen ZLE; Voskuyl AE; Broens B; Sanchez AP; Wolbink G; Boekel L; Rutgers A; de Leeuw K; Horváth B; Verschuuren JJGM; Ruiter AM; van Ouwerkerk L; van der Woude D; Allaart CF; Teng YKO; van Paassen P; Busch MH; Jallah BP; Brusse E; van Doorn PA; Baars AE; Hijnen D; Schreurs CRG; van der Pol WL; Goedee HS; Steenhuis M; Rispens T; Ten Brinke A; Verstegen NJM; Zwinderman KAH; van Ham SM; Kuijpers TW; Eftimov F;
    BMC Med; 2022 Mar; 20(1):100. PubMed ID: 35236350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy.
    Syversen SW; Jyssum I; Tveter AT; Sexton J; Christensen IE; Tran TT; Bjørlykke KH; Mjaaland S; Warren DJ; Kvien TK; Chopra A; Kro GB; Jahnsen J; Munthe LA; Haavardsholm EA; Grødeland G; Vaage JT; Provan SA; Jørgensen KK; Goll GL
    RMD Open; 2022 Nov; 8(2):. PubMed ID: 36328399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases.
    Simon D; Tascilar K; Fagni F; Krönke G; Kleyer A; Meder C; Atreya R; Leppkes M; Kremer AE; Ramming A; Pachowsky ML; Schuch F; Ronneberger M; Kleinert S; Hueber AJ; Manger K; Manger B; Berking C; Sticherling M; Neurath MF; Schett G
    Ann Rheum Dis; 2021 Oct; 80(10):1312-1316. PubMed ID: 33958324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination.
    Firinu D; Perra A; Campagna M; Littera R; Fenu G; Meloni F; Cipri S; Sedda F; Conti M; Miglianti M; Costanzo G; Secci M; Usai G; Carta MG; Cappai R; Orrù G; Del Giacco S; Coghe F; Chessa L
    Clin Exp Med; 2022 Aug; 22(3):477-485. PubMed ID: 34741188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral and cellular responses to spike of δ SARS-CoV-2 variant in vaccinated patients with immune-mediated inflammatory diseases.
    Petrone L; Picchianti-Diamanti A; Sebastiani GD; Aiello A; Laganà B; Cuzzi G; Vanini V; Gualano G; Grifoni A; Ferraioli M; Castilletti C; Meschi S; Vaia F; Nicastri E; Sette A; Goletti D
    Int J Infect Dis; 2022 Aug; 121():24-30. PubMed ID: 35462039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The long term vaccine-induced anti-SARS-CoV-2 immune response is impaired in quantity and quality under TNFα blockade.
    Geisen UM; Rose R; Neumann F; Ciripoi M; Vullriede L; Reid HM; Berner DK; Bertoglio F; Hoff P; Hust M; Longardt AC; Lorentz T; Martini GR; Saggau C; Schirmer JH; Schubert M; Sümbül M; Tran F; Voß M; Zeuner R; Morrison PJ; Bacher P; Fickenscher H; Gerdes S; Peipp M; Schreiber S; Krumbholz A; Hoyer BF
    J Med Virol; 2022 Dec; 94(12):5780-5789. PubMed ID: 35945627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease.
    Haberman RH; Herati RS; Simon D; Samanovic M; Blank RB; Tuen M; Koralov SB; Atreya R; Tascilar K; Allen JR; Castillo R; Cornelius AR; Rackoff P; Solomon G; Adhikari S; Azar N; Rosenthal P; Izmirly P; Samuels J; Golden B; Reddy S; Neurath M; Abramson SB; Schett G; Mulligan MJ; Scher JU
    medRxiv; 2021 May; ():. PubMed ID: 34013285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy.
    Syversen SW; Jyssum I; Tveter AT; Tran TT; Sexton J; Provan SA; Mjaaland S; Warren DJ; Kvien TK; Grødeland G; Nissen-Meyer LSH; Ricanek P; Chopra A; Andersson AM; Kro GB; Jahnsen J; Munthe LA; Haavardsholm EA; Vaage JT; Lund-Johansen F; Jørgensen KK; Goll GL
    Arthritis Rheumatol; 2022 Aug; 74(8):1321-1332. PubMed ID: 35507355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune-mediated inflammatory diseases.
    Dayam RM; Law JC; Goetgebuer RL; Chao GY; Abe KT; Sutton M; Finkelstein N; Stempak JM; Pereira D; Croitoru D; Acheampong L; Rizwan S; Rymaszewski K; Milgrom R; Ganatra D; Batista NV; Girard M; Lau I; Law R; Cheung MW; Rathod B; Kitaygorodsky J; Samson R; Hu Q; Hardy WR; Haroon N; Inman RD; Piguet V; Chandran V; Silverberg MS; Gingras AC; Watts TH
    JCI Insight; 2022 Jun; 7(11):. PubMed ID: 35471956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effect of Exposure to SARS-CoV-2 Vaccination and Infection on Humoral and Cellular Immunity in a Cohort of Patients with Immune-Mediated Diseases: A Pilot Study.
    Costanzo GAML; Sanna G; Pes F; Deiana CM; Ledda AG; Perra A; Palmas V; Manca V; Miglianti M; Coghe F; Manzin A; Del Giacco S; Chessa L; Firinu D
    Pathogens; 2024 Jun; 13(6):. PubMed ID: 38921803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.